This site is intended for healthcare professionals
Latest drug news
  • Home
  • /
  • News
  • /
  • 2023
  • /
  • 9
  • /
  • FDA accepts BLA for AVT 02 adalimumab biosimilar f...

FDA accepts BLA for AVT 02 adalimumab biosimilar from Alvotech.

Read time: 1 mins
Published:21st Sep 2023

Alvotech announced that the FDA has accepted Alvotech’s resubmitted Biologics License Application (BLA) for AVT 02, a high-concentration, interchangeable biosimilar candidate to Humira (adalimumab). The FDA has also announced a Biosimilar User Fee Act (BsUFA) goal date for approval of the resubmitted AVT 02 BLA. The BsUFA goal date provided by the FDA is February 24, 2024.

The FDA indicated that Alvotech’s resubmission is considered to be a complete response to the agency’s June 28, 2023, action letter, given the additional Chemistry, Manufacturing and Controls information submitted by the Company with the BLA to address manufacturing facility deficiencies identified earlier by the FDA.

An interchangeable biosimilar may be substituted at the pharmacy without the intervention of the healthcare professional who prescribed the originator biologic, subject to variations in state pharmacy laws and practices. No interchangeable high-concentration adalimumab biosimilar is currently available to U.S. patients.

Condition: RA/AnkSpon/Crohns/UC/PsA/Ps
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.